Willis C. Lee - 26 Feb 2024 Form 4 Insider Report for Emmaus Life Sciences, Inc. (EMMA)

Role: Co-President & COO, Director
Signature: Willis C. Lee
Issuer symbol: EMMA
Transactions as of: 26 Feb 2024
Net transactions value: +$14,694
Form type: 4
Filing time: 29 Feb 2024, 18:11:11 UTC
Previous filing: 05 Feb 2024
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	EMMA	Common stock, $0.001 par value	Purchase	$1,584	+13,200	+30%	$0.1200	57,400	26 Feb 2024	By Fidelity Roth IRA FBO Willis C. Lee	F1
transaction	EMMA	Common stock, $0.001 par value	Purchase	$1,300	+10,000	+17%	$0.1300	67,400	27 Feb 2024	By Fidelity Roth IRA FBO Willis C. Lee
transaction	EMMA	Common stock, $0.001 par value	Purchase	$1,800	+15,000	+22%	$0.1200	82,400	28 Feb 2024	By Fidelity Roth IRA FBO Willis C. Lee	F2
transaction	EMMA	Common stock, $0.001 par value	Purchase	$10,010	+77,000	+93%	$0.1300	159,400	29 Feb 2024	By Fidelity Roth IRA FBO Willis C. Lee
holding	EMMA	Common stock, $0.001 par value						395,124	26 Feb 2024	Direct
holding	EMMA	Common stock, $0.001 par value						241,194	26 Feb 2024	By Fidelity Traditional IRA FBO Willis C. Lee

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.12 to $0.13, inclusive. The reporting person undertakes to provide to Emmaus Life Sciences, Inc., any security holder of Emmaus Life Sciences, Inc., and the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (1) and in footnote (2) to this Form 4.
F2	The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.12 to $0.13, inclusive.

Content

The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.12 to $0.13, inclusive. The reporting person undertakes to provide to Emmaus Life Sciences, Inc., any security holder of Emmaus Life Sciences, Inc., and the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (1) and in footnote (2) to this Form 4.

The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.12 to $0.13, inclusive.